Erlotinib plus bevacizumab for EGFR-mutant advanced non-squamous non-small-cell lung cancer patients: ready for first-line?

Ítems similars

• Gefitinib Plus Bevacizumab vs. Gefitinib Alone for EGFR Mutant Non-squamous Non-small Cell Lung Cancer
  per: KITAGAWA, CHIYOE, et al.
  Publicat: (2019)
• Effect of Erlotinib Plus Bevacizumab vs Erlotinib Alone on Progression-Free Survival in Patients With Advanced EGFR-Mutant Non–Small Cell Lung Cancer: A Phase 2 Randomized Clinical Trial
  per: Stinchcombe, Thomas E., et al.
  Publicat: (2019)
• Response to Erlotinib in Patients with EGFR Mutant Advanced Non-Small Cell Lung Cancers with a Squamous or Squamous-like Component
  per: Paik, Paul K., et al.
  Publicat: (2012)
• Immunotherapy in tyrosine kinase inhibitor-naïve advanced epidermal growth factor receptor-mutant non-small cell lung cancer—driving down a precarious road in driver-mutated lung cancer
  per: Tay, Rebecca Yin, et al.
  Publicat: (2018)
• Evaluation of plasma EGFR mutation as an early predictor of response of erlotinib plus bevacizumab treatment in the NEJ026 study
  per: Fukuhara, Tatsuro, et al.
  Publicat: (2020)